Cellebrite DI Target of Unusually Large Options Trading (NASDAQ:CLBT)

Cellebrite DI Ltd. (NASDAQ:CLBT) was the recipient of unusually large options trading on Thursday. Stock traders acquired 19,988 call options on the company. This represents an increase of 3,311% compared to the typical volume of 586 call options.

Insider Buying and Selling at Cellebrite DI

In other Cellebrite DI news, CRO Marcus Jewell sold 12,658 shares of the stock in a transaction on Monday, May 18th. The stock was sold at an average price of $12.77, for a total transaction of $161,642.66. Following the completion of the transaction, the executive directly owned 440,101 shares of the company’s stock, valued at approximately $5,620,089.77. This trade represents a 2.80% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO David Barter sold 41,734 shares of Cellebrite DI stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $16.38, for a total value of $683,602.92. Following the transaction, the chief financial officer owned 334,219 shares in the company, valued at approximately $5,474,507.22. This trade represents a 11.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 297,934 shares of company stock valued at $4,631,972. 5.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Roubaix Capital LLC grew its stake in Cellebrite DI by 108.1% in the first quarter. Roubaix Capital LLC now owns 303,215 shares of the company’s stock valued at $4,178,000 after purchasing an additional 157,536 shares in the last quarter. Lazard Asset Management LLC acquired a new position in Cellebrite DI in the 1st quarter worth about $2,134,000. Principal Financial Group Inc. increased its position in Cellebrite DI by 33.9% in the 1st quarter. Principal Financial Group Inc. now owns 2,156,166 shares of the company’s stock worth $29,712,000 after purchasing an additional 545,334 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its stake in shares of Cellebrite DI by 28.6% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,350,000 shares of the company’s stock worth $24,341,000 after purchasing an additional 300,000 shares in the last quarter. Finally, Weiss Asset Management LP lifted its holdings in shares of Cellebrite DI by 3,485.3% during the 1st quarter. Weiss Asset Management LP now owns 1,899,841 shares of the company’s stock valued at $26,180,000 after buying an additional 1,846,851 shares during the last quarter. 45.88% of the stock is owned by hedge funds and other institutional investors.

Cellebrite DI Stock Up 3.1%

Shares of CLBT traded up $0.34 during mid-day trading on Friday, reaching $11.14. The company’s stock had a trading volume of 7,844,977 shares, compared to its average volume of 2,966,804. The business has a fifty day moving average of $14.47 and a 200 day moving average of $14.03. The company has a market cap of $2.78 billion, a price-to-earnings ratio of 50.64, a price-to-earnings-growth ratio of 1.34 and a beta of 1.18. Cellebrite DI has a 1 year low of $9.58 and a 1 year high of $19.98.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings data on Thursday, August 13th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.05. Cellebrite DI had a return on equity of 16.04% and a net margin of 11.43%.The firm had revenue of $131.14 million during the quarter, compared to analyst estimates of $131.50 million. On average, analysts predict that Cellebrite DI will post 0.41 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on CLBT shares. JPMorgan Chase & Co. lowered their target price on Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating on the stock in a report on Friday. Lake Street Capital reduced their price objective on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a research report on Friday. Needham & Company LLC lowered their price objective on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating on the stock in a research note on Friday. Weiss Ratings downgraded shares of Cellebrite DI from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday. Finally, DA Davidson dropped their price target on Cellebrite DI from $22.00 to $15.00 and set a “buy” rating on the stock in a report on Friday. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Cellebrite DI presently has an average rating of “Moderate Buy” and an average price target of $16.70.

Key Stories Impacting Cellebrite DI

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Second-quarter adjusted EPS was $0.11, above the $0.05 consensus estimate cited by MarketBeat. Management also raised its adjusted EBITDA target, while subscription revenue continued to grow. Cellebrite second-quarter earnings report
• Positive Sentiment: Lake Street, JPMorgan, D.A. Davidson and Needham lowered their price targets but retained positive ratings: Buy or Overweight. Their revised targets range from $12.50 to $16, implying roughly 12% to 44% upside based on the provided reference price. Analyst price-target updates
• Positive Sentiment: Unusual options activity included nearly 20,000 call contracts, far above average volume, indicating speculative positioning for a potential rebound.
• Neutral Sentiment: Cellebrite completed a planned CEO transition, with Shiven Ramji succeeding Thomas E. Hogan effective August 13. The change may support a strategic reset, but investors face uncertainty during the leadership handoff. CEO succession announcement
• Negative Sentiment: The key catalyst for the selloff was lowered guidance. Third-quarter revenue is expected at $145 million-$148 million, below the $150.3 million consensus, while full-year revenue guidance of $555 million-$561 million trails the $568.1 million estimate. The company also reduced its 2026 ARR outlook. Cellebrite outlook announcement
• Negative Sentiment: Quarterly revenue of $131.14 million was slightly below the $131.87 million estimate. The earnings beat was therefore overshadowed by weaker growth indicators and the reset to management’s outlook.
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations and whether prior projections and disclosures were accurate. The investigations are allegations, not findings, but add legal and reputational risk. Cellebrite investigation notice
• Negative Sentiment: Former CEO Thomas Hogan sold 139,713 shares worth approximately $2.15 million, reducing his holdings by about 15%. Although the sale may reflect the transition or personal financial planning, its timing weighs on investor sentiment. SEC insider trading filing

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.